[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100521902":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":23,"centralContacts":28,"locations":34,"responsibleParty":52,"collaborators":10,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":10,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":10,"enrollmentInfo":63,"targetDuration":10,"studyType":66,"phases":10,"briefSummary":67,"conditions":68,"keywords":10,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Kansas City Heart Rhythm Research Foundation","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Amplatzer Amulet",null,"This is the group of subjects who are implanted with Amplatzer Amulet device.",[13],"Other: Left Atrial Appendage Occlusion",{"label":15,"type":10,"description":16,"interventionNames":17},"Watchman \u002F Watchman FLX","This is the group of subjects who are implanted with Watchman \u002F Watchman FLX device.",[13],[19],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"Left Atrial Appendage Occlusion","Acute ischemic stroke is a major cause of morbidity and mortality in non-valvular Atrial Fibrillation (AF). Oral Anticoagulation (OAC) with Warfarin and Direct oral anticoagulants (DOACs) has been the mainstay to prevent systemic thromboembolism (STE) in this patient population. It is estimated that around 50% of patients who have AF with indication for OAC end up being not on OAC due to bleeding complications leaving them at high risk for developing STE. Left atrial appendage occlusion (LAAO) offers an option in such population.",[9,15],[24],{"name":25,"affiliation":26,"role":27},"Dhanunjaya Lakkireddy, MD","Kansas City Heart Rhythm Institute","PRINCIPAL_INVESTIGATOR",[29],{"name":30,"role":31,"phone":32,"phoneExt":10,"email":33},"Donita Atkins","CONTACT","816-651-1969","datkins@kchrf.com",[35],{"facility":26,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Overland Park","Kansas","66211","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-94.67079,38.98223,{"lat":46,"lon":45},[49,51],{"name":30,"role":31,"phone":32,"phoneExt":10,"email":50},"Datkins@kchrf.com",{"name":25,"role":27,"phone":10,"phoneExt":10,"email":10},{"type":53,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100521902","long-term-outcomes-of-laa-contrast-flow-in-ct-scans-after-endocardial-laa-closure-the-cf-ct-registry-100521902",false,"NCT06075628","Long-Term Outcomes of LAA Contrast Flow in CT Scans After Endocardial LAA Closure: The CF-CT Registry","Long-Term Outcomes of Left Atrial Appendage Contrast Flow in CT Scans After Endocardial LAA Closure: The CF-CT Registry","Inclusion Criteria:\n\n* Subjects must be at least 18 years of age.\n* Subjects underwent LAA closure with Watchman\u002FWatchman FLX or Amplatzer Amulet at our institution from January 2019 till June 2022\n\nExclusion Criteria:\n\n* No definite exclusion criteria are defined for the study as all patients with Watchman-FLX or Amplatzer Amulet will be included in the study.","ALL","18 Years",{"count":64,"type":65},100,"ESTIMATED","OBSERVATIONAL","This study is intended to assess the incidence and correlation to the development of peri-device leaks (PDLs), device related thrombosis (DRTs) and cerebral vascular accident (CVA)\u002Ftransient ischemic attacks (TIAs) in association with left atrial appendage contrast flow (LAA-CF). It will be a multi-center, retrospective study. Approximately 100 subject charts will be reviewed.",[69,70],"Atrial Fibrillation","Ischemic Stroke, Acute","2025-08-27",{"date":73,"type":74},"2025-08-28","ACTUAL",{"date":76,"type":74},"2023-07-24",{"date":78,"type":65},"2025-12",{"name":5,"class":6},1]